Recent Posts
- Hikma v. Vanda: Oral Argument Recap
- Teva v. Lilly should not be read as creating a new 112 rule for method of use claims
- Should ANDA filers be using the PTAB to mount early challenges to OB patents?
- Switching to WordPress
- Judge Hughes concurrence highlights post grant review appeal standing issue for pharma cases
Category: Infringement–271(g)
-
Momenta and Sandoz v. Teva, No. 2014-1274 (Fed. Cir.) Momenta and Sandoz v. Amphastar, No. 2014-1276 (Fed. Cir.) by Aaron F. Barkoff In a precedential opinion today, in companion cases concerning generic enoxaparin, the Federal Circuit reached two decisions that pharmaceutical companies should take note of: 1. Teva's enoxaparin is not "made by" a patented…
Orange Book Blog 